Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: mannose receptor-targeted therapeutic agents - Navidea Biopharmaceuticals

Next Previous
Drug Profile

Research programme: mannose receptor-targeted therapeutic agents - Navidea Biopharmaceuticals

Alternative Names: Cy3-Manocept-doxorubicin; Cy3-manocept-therapeutics; MT 1000; MT 1001; MT 2000; MT 2001; MT-1002; MT-2002

Latest Information Update: 28 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Navidea Biopharmaceuticals
  • Developer Macrophage Therapeutics; Navidea Biopharmaceuticals; Unknown
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antituberculars; Antivirals; Cardiovascular therapies; Hepatoprotectants; Immunotherapies; Neuroprotectants; Steroids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Cardiovascular disorders; CNS disorders; Crohn's disease; Infections; Inflammatory bowel diseases; Kaposi's sarcoma; Non-alcoholic fatty liver disease

Most Recent Events

  • 28 May 2023 No recent reports of development identified for preclinical development in Cancer in USA
  • 08 Nov 2022 Preclinical pharmacodynamic data in Cancer released by Navidea
  • 15 Aug 2022 Navidea Biopharmaceuticals receives notification of issuance of patent for compounds, compositions and methods for using it in diagnosis and treating Leishmaniasis, in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top